Effects of TNF Blockade on Human BPH/LUTS
Specific Aim 1. To evaluate the efficacy of TNF antagonist action in BPH/LUTS Specific Aim 2. Define the consequences of TNF antagonist therapy on prostate tissue Specific Aim 3. Identify genetic predictors to stratify patients with differential response to TNF-antagonist therapy.
• Male sex
• Age 45-80 years
• Diagnosed by physician with BPH
• Prostate volume ≥ 60mL
• IPSS ≥ 8
• Able and willing to complete questionnaires
• Able and willing to provide informed consent
• Able to read, write, and speak in English
• No prior treatment with TNF inhibitor (adalimumab, etanercept, infliximab, certolizumab, golimumab)
• No plans to move from study area in the next 6 months
⁃ Deferral Criteria:
• Microscopic hematuria without appropriate workup per AUA/Society of Urodynamics, Female Pelvic Medicine \& Urogenital Reconstruction (SUFU) Guidelines
• Positive urine culture